Qure.ai has secured approval from the US Food and Drug Administration (FDA)
for its head CT scan product, making it the first Indian artificial intelligence (AI) company to receive such recognition.
Qure.ai's AI tool is designed to assist in triaging radiology scans with intracranial bleeds, mass effect, midline shift, and cranial fractures. Two of these capabilities, detecting cranial fractures and midline shift, are exclusive to Qure.ai's product, qER.
"The sooner doctors have in-depth information, the better for the patient. This is where qER plays a key role," explained Pooja Rao, co-founder of Qure.ai. The tool plugs directly into the radiology workflow, enabling the prioritization of critical cases for quicker diagnosis and improved patient outcomes.
In addition to qER, Qure.ai has also developed a CE-marked chest X-ray AI tool and Covid-19 progression monitoring solutions for chest X-rays, both currently in clinical use in over 20 countries.
The company notes the necessity for a comprehensive imaging AI tool, given the high volume of CT scans performed annually in the US and the mortality rates post-emergency room discharge.